The Forefront of Innovation

About Us

Scientist.com is on a mission to empower and connect researchers worldwide.

By enabling scientists to easily Outsource Everything But the GeniusTM, we are pioneering a faster, leaner and more innovation-centric approach to research. Our vision is to create a world in which scientists are limited only by their imagination.

Our partners include large and small pharmaceutical and biotechnology companies, crop science companies, cosmetic companies, Contract Research Organizations (CROs), government research institutes, university core facilities, academic researchers and citizen scientists.

Management

Kevin Lustig, PhD
CEO & President

Kevin is a scientist-entrepreneur with 30 years of research experience in academia and pharma. He co-founded Scientist.com in 2007. In 2001, he co-founded Kalypsys, a small pharmaceutical company. He was Director of Lead Discovery at Tularik from 1997-2001. He carried out postdoctoral work at Harvard Medical School after receiving a PhD degree from Marc Kirschner’s laboratory at UC-San Francisco and an A.B. degree, magna cum laude, from Cornell University.

Chris is a software engineer who has worked extensively with drug researchers to develop online solutions to complex scientific processes. He co-founded Scientist.com in 2007. From 2002-2006 he was Director of Software Development at Kalypsys, a small pharmaceutical company. He was Director of Engineering at Learning Framework from 1999-2001. Chris received a B.S. degree in Computer Science from Worcester Polytechnic Institute, where he received the Provost’s award.

Dan is a bioengineer who has worked extensively with life science start-up companies. Prior to joining Scientist.com, he advised startups at eBoost Consulting, started a company called ChemoTactics and was the CTO of the UC-San Diego 100K Entrepreneur Challenge. In 2012, Dan was selected as a Siebel Scholar. Dan received an M.S. and Ph.D in Bioengineering from Joseph Wang’s lab at UCSD, where he was a Gordon Scholar. He received a B.S. degree, summa cum laude, from Rutgers in 2006.

Board Of Directors

SCI-PHinshaw

Parker Hinshaw

Bootstrap Ventures


Parker Hinshaw was previously the CEO/founder of maxIT Healthcare, a consulting services company that was sold in 2015 for $500M+. He is now senior vice president of business development for MD Revolution. A successful leader over his 35-year career, Parker now sits on the boards and advises multiple innovative organizations and start-ups. Parker received a Bachelor of Business Administration (BBA) from Indiana University.

SCI-AMartin

Andrew B. Martin, PhD

Informatics Specialist, Stanford University School of Medicine


Andy is an informatics expert specializing in the organization, analysis and visualization of big data. He co-founded Scientist.com in 2007. Currently, he builds tools to securely store clinical patient data at Stanford University. From 1999-2006, he was head of informatics at Kalypsys, a small pharmaceutical company. He received a PhD degree in Chemistry from Peter Schultz’s laboratory at the UC-Berkeley and a B.A. degree magna cum laude from Carleton College.

Jared A. Kesselheim

Jared A. Kesselheim, MD

Managing Partner, Leerink Transformation Partners


Co-founder and Managing Partner of Leerink Transformation Partners and co-leader of the firm’s growth equity investing in healthcare information technology and services. Prior to forming LTP in 2016, Jared was a Partner and the leader of the healthcare investing practice at Bain Capital Ventures. Jared also completed a residency in Internal Medicine at Massachusetts General Hospital.

Paul A. Stone, JD

Paul A. Stone, JD

Partner, 5AM Ventures


Paul A. Stone, J.D. is a Partner of 5AM Ventures. Paul joined in July 2009 as General Counsel and Chief Operating Officer and was promoted to Partner in January 2016. Previously he was Senior VP, General Counsel and Chief Patent Counsel at Ilypsa (acquired by Amgen). He received his J.D. from the University of Wisconsin Law School and practiced as a Patent Attorney at Senniger, Powers, Leavitt & Roedel. After receiving his degree in Chemical Engineering, University of Wisconsin – Madison, Paul served as a Naval Officer on the USS NIMITZ.

Kevin

Kevin Lustig, PhD

CEO and President, Scientist


Kevin is a scientist-entrepreneur with 30 years of research experience in academia and pharma. He co-founded Scientist.com in 2007. In 2001, he co-founded Kalypsys, a small pharmaceutical company. He was Director of Lead Discovery at Tularik from 1997-2001. He carried out postdoctoral work at Harvard Medical School after receiving a PhD degree from Marc Kirschner’s laboratory at UC-San Francisco and an A.B. degree, magna cum laude, from Cornell University.

Scientific Advisory Board

SCI-T-Torphy

Ted J. Torphy, PhD

Chief Science Officer, BioMotiv


With more than 30 years of experience in pharmaceutical R&D, Ted has been instrumental in the discovery and development of multiple marketed products. Since 2004 he has chaired the board of The Cystic Fibrosis Foundation Therapeutics, Inc. Ted currently serves as CSO of BioMotiv. Prior to that, Ted spent 12 years with Johnson & Johnson in high ranking managerial positions. Before Johnson & Johnson, Ted spent 17 years with SmithKline Beecham in various VP tier roles. He holds a B.S. degree in Pharmacy from the University of Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University.

SCI-RKing

Randall W. King, MD PhD

Professor, Harvard Medical School


Randall is a Professor in the Department of Cell Biology at Harvard Medical School. Prior to joining the faculty at Harvard Medical School, Dr. King was a fellow at the Institute of Chemistry and Cell Biology at Harvard, where he developed new approaches in chemical genetics. Dr.King co-founded the drug discovery company Kalypsys in 2001, and served on its science advisory board for four years. He received an MD from Harvard Medical School after receiving a PhD from Mark Kirschner’s laboratory at the University of California, San Francisco. He received a B.A. degree in chemistry from Carleton College.

SCI-AButte

Atul Butte, MD PhD

Director of the Institute for Computational Health Sciences; Executive Director of Clinical Informatics for UC Health Sciences and Services and Professor of Pediatrics at UCSF


Atul is Director of the Institute for Computational Health Sciences and Professor of Pediatrics at UCSF. Atul studied Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, then received his PhD in Health Sciences and Technology from Harvard Medical School and MIT. He is also a founder of Personalis and NuMedii. Atul authored more than 120 publications and delivered more than 140 presentations. His recent awards include the 2011 National Human Genome Research Institute Genomic Advance of the Month and the 2010 Society for Pediatric Research Young Investigator Award.

SCI-Jtheriot

Julie A. Theriot, PhD

Professor, Stanford University


Julie is a Professor at the Stanford University School of Medicine, with appointments in the Department of Biochemistry and the Department of Microbiology & Immunology. Her group has developed computational, analytical and statistical methods for large-scale quantitative image and motion analysis. She has numerous awards for both research and teaching, including a MacArthur Foundation fellowship in 2004. Prior to 1997, Dr. Theriot was a Whitehead Fellow at the Whitehead Institute for Biomedical Research. She received a PhD in Cell Biology from the University of California at San Francisco in 1993, and BS degrees in Biology and Physics from MIT in 1988.

SCI-BConklin

Bruce Conklin, MD

Sr Investigator Gladstone Inst. and Professor UCSF


Bruce is a Senior Investigator at the Gladstone Institute and a Professor at the University of California, San Francisco. Dr. Conklin received an A.B. degree in public health from UC Berkeley in 1982. He completed an MD degree at Case Western Reserve University in Cleveland in 1988. From 1995 to 2001, Dr. Conklin was the Associate Director of the General Clinical Research Center at San Francisco General Hospital. Dr. Conklin was the co-chair of the UCSF public science project in 1994, and is co-chair of the UCSF-California Academy of Sciences Affiliation Task Force.

Jeffrey Hager, PHD

Jeffrey Hager, PHD

Co-Founder, Senior Vice President and Head of Biology, IDEAYA Biosciences


Since November 2015, Jeff has served as co-founder and Senior Vice President and Head of Biology at IDEAYA Biosciences. Prior to IDEAYA, he was VP of Biology at Seragon Pharmaceuticals, which was acquired by Roche/Genentech for up to $1.7 billion. Previously, Jeff was Senior Director at Aragon Pharmaceuticals, which was acquired by Johnson & Johnson for up to $1 billion. Prior to Aragon, he was Associate Director of Biology at Apoptos, Inc. and Head of Cancer Pharmacology at Kalypsys, Inc. He did graduate studies at both Princeton and University of California at Berkeley, the latter from which he received a PhD in molecular and cell biology.  He was also a postdoctoral fellow and staff scientist at the University of California at San Francisco.

Andrew Hessel, PHD

Andrew Hessel, PHD

Autodesk Distinguished Researcher; Co-Founder of the Pink Army Cooperative


Autodesk Distinguished Researcher Andrew Hessel is a catalyst in biological technologies, helping industry, academics and authorities better understand the changes happening in life science. He is also the co-founder of the Pink Army Cooperative, the world’s first cooperative biotechnology company. He is a fellow at the University of Ottawa, Institute for Science, Society, and Policy and the former co-chair of bioinformatics and biotechnology at Singularity University.

Andrew Shiau, PHD

Andrew Shiau, PHD

Small Molecule Discovery Program Director, Ludwig Institute (San Diego Branch)


Andrew is Director of the Small Molecule Discovery Program at the San Diego branch of the Ludwig Institute where he leads a highly collaborative, systematic effort to use chemical biology to translate the cutting-edge research of Ludwig scientists into new cancer medicines. Before joining Ludwig in 2009, he was Director of Biology at Kalypsys, Inc. Before that, Andrew was head of the Orphan Nuclear Receptor Program at Tularik.  He received his PhD in biochemistry and biophysics from the University of California, San Francisco.

Michael Jackson, PHD

Michael Jackson, PHD

Senior Vice President of Drug Discovery and Development, Sanford Burnham Prebys Medical Discovery Institute


Michael is Senior Vice President of Drug Discovery and Development at Sanford Burnham Prebys Medical Discovery Institute. He works closely with SBP’s senior leadership to seek new avenues of support for preclinical and clinical drug development initiatives to enable the overall mission of the Institute to translate basic research to new products. Prior to this, Michael was Chief Scientific Officer at Johnson & Johnson. He received his PhD in molecular biology/ toxicology from the University of Dundee in Scotland.